

Special Issue

Towards Precision Medicine in Psychosis

Message from the Guest Editor

Precision medicine has been considered a promising diagnostic and therapeutic approach in psychiatry for the purpose of improving disease prevention, thereby increasing effectiveness and reducing adverse effects, based on the individual patient's clinical and biological characteristics. Since it has been reported that structural and functional brain abnormalities are related to the early stages of psychosis, it is estimated that these findings can contribute to the prediction of clinical onset and outcome. Despite its advancement, precision medicine in psychosis remains in the early phase, since there have been several limitations including a small sample size, low statistical power, lack of external validation for identified biomarkers, and others. This Special Issue aims to highlight the current scientific knowledge and reveal some of the latest findings in the field of precision medicine with respect to psychosis. Candidate biomarkers that are based on clinical, genetic, and neuroimaging approaches or combinations thereof may be investigated.

Guest Editor

Prof. Dr. Seon-Cheol Park

Department of Psychiatry, Hanyang University College of Medicine,
Seoul 02841, Korea

Deadline for manuscript submissions

closed (30 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/88723

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).